The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: ...

ALS patients and their caregivers benefit most from flexible psychological support that combines emotional care, open ...

Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral ...

NEW ORLEANS--(BUSINESS WIRE)--In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) ...

COUNTY SHERIFF’S DEPARTMENT. WELL, IMAGINE HAVING A MEDICINE HELPING TO KEEP YOU ALIVE AND SUDDENLY IT IS GONE. WE’RE HEARING FROM A WOMAN LIVING WITH ALS OR LOU GEHRIG’S DISEASE, WHO SAYS SHE MAY BE ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...

In a landmark continuing collaboration, Answer ALS and Cedars-Sinai have announced the completed availability of the largest amyotrophic lateral sclerosis (ALS) patient-based induced pluripotent stem ...

Allowing people with disabilities to talk by just thinking about a word, that's what UC Davis researchers hope to accomplish with new cutting-edge technology. It can be a breakthrough for people with ...

Unprecedented resource, created with Cedars-Sinai, to accelerate ALS research and drive development of targeted therapies globally NEW ORLEANS, [November 14, 2024] — In a landmark continuing ...